Lilly rides Mounjaro, Zepbound to better
Time:2024-05-21 17:49:55 Source:politicsViews(143)
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Previous:Travis Kelce downs whiskey shot on slice of bread at Kelce Jam without Taylor Swift
Next:Supreme Court declines to hear challenge to Maryland ban on rifles known as assault weapons
You may also like
- Here comes the char
- Government agrees to slash road user charges for plug
- Dame Kiri Te Kanawa honoured for her achievements in Parliament
- The Iron Claw review: The Big Daddy of wrestling movies
- Socialite Jasmine Hartin enjoys beach snuggle with electrician hunk
- ALISON BOSHOFF: Yo ho ho! Johnny Depp to launch his own brand of Caribbean dark rum
- Awkward moment pregnant mother is left in tears after discovering she's having a third son
- Rustle these up with Rosemary: My traditional steak and kidney pie
- Iran helicopter crash that killed President Raisi could reverberate across the Middle East